ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 213

Nsaids Suppress the Inflammatory Reaction Related to Muscle Soreness but May Delay Recovery

Matthias Rother1, Egbert J. Seidel2, Alexander Fischer2 and Ilka Rother1, 1IMR Partner GmbH, Graefelfing, Germany, 2Department of Physical and Rehabilitation Medicine, Sophien- and Hufeland Clinic, Weimar, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Etoricoxib, Inflammation, muscle strength and pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Clinical and Therapuetic Aspects of Idiopathic Inflammatory Myopathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Eccentric muscle contraction causes an inflammatory reaction with pain peaking 24 to 48 hours after exercise – delayed onset of muscle soreness (DOMS). NSAIDs are used frequently for treatment or even prevention of DOMS. But evidence for treatment effects of NSAIDs is controversial. Timing of intervention and pharmacological properties of the specific NSAID tested might explain the controversial results. In two previous studies using a daily life oriented model of DOMS induced by walking down stairs we found for 200 mg celecoxib when given about 16 h after exercise a modest, insignificant reduction in pain [Phys Med Rehab Kuror 2012; 22: 57–63]. Ketoprofen (100 mg bid), a higher potent anti-inflammatory drug, caused a delay in recovery from DOMS when given immediately after exercise [Phys Med Rehab Kuror 2012; accepted for publication].This study investigated the effects of a Cox-2 inhibitor (90 mg qd etoricoxib) on markers of inflammation, pain and muscle force after eccentric exercise.

Methods: Randomized, double-blind, placebo-controlled, cross over study in 50 healthy subjects exposed to equipment based, eccentric exercise of the lower limb (“extrafit Beinstrecker”, extrafit INVESTMENT GmbH, Germany). Subjects with pain during muscle contraction of at least 5 on an 0-10 point categorical scale at 16±2 h after exercise were eligible for randomization. Pain at rest and during contraction, muscle force, pain threshold at tender point and markers of inflammation (high sensitive C-reactive Protein (hsCrP), sedimentation rate, leucocyte number) were evaluated at various time points during the treatment period of 7 days.

Results: There is a non significant trend for reduction of pain at rest with etoricoxib treatment for the first 24 h of treatment (etoricoxib: 10.4±9.7, placebo: 11.5±9.9). For peak torque and pain threshold at the tender point, there is a trend of delayed recovery with etoricoxib treatment. HsCrP is increased due to DOMS and showed significant cross-over effects (p=0.0089). The carry-over effect might be due to anti-inflammatory effects of etoricoxib in period I (p=0.0341) carried over into period II. This is in line with the overall result indicating a significant long term anti-inflammatory effect evident through a reduction in hsCrP as compared to placebo (p=0.0203). Overall, also a trend of reduction in model induced increase of leucocytes (p=0.0981) was shown. Sedimentation rate was insensitive to the model and treatment effects.

Conclusion: Equipment based eccentric exercise of the lower limbs appears to be a robust model of muscle pain. This approach allows the design of cross-over studies since the exercise load can be individualized and adapted to differences in muscle force of the dominant vs. non-dominant limb. Treatment related effects are in line with previous studies indicating a modest analgesic effect but evidence for delayed recovery. This supports the concept that the inflammatory reaction is an essential part of the recovery process. Anti-inflammatory treatment might cause a delay in recovery. Caution should be used when using NSAIDs for the treatment of exercise induced muscle pain.


Disclosure:

M. Rother,

MSD Sharp & Dohme GmbH,

2;

E. J. Seidel,

IMR Partner GmbH,

5;

A. Fischer,

IMR Partner GmbH,

5;

I. Rother,

IMR Partner GmbH,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nsaids-suppress-the-inflammatory-reaction-related-to-muscle-soreness-but-may-delay-recovery/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology